MedTrace Logo

ALS Reversals - Lunasin Regimen

NCT02709330 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-12-13

Study results available
· View outcomes & findings →

Summary

This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group. Participants will receive a Lunasin regimen and will be asked to register for an account of PatientsLikeMe website, where after the initial in-clinic visit, they will be asked to enter specific data.

Conditions

  • ALS (Amyotrophic Lateral Sclerosis)

Interventions

DRUG

Lunasin Regimen

LunaRich X Capsules, Reliv Now, ProVantage

OTHER

Historical control

Matched historical controls will be identified from the PatientsLikeMe database.

Sponsors & Collaborators

  • Richard Bedlack, M.D., Ph.D.

    lead OTHER

Principal Investigators

  • Richard Bedlack, M.D., Ph.D. · Associate Professor of Neurology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-09-13
Completion
2017-09-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02709330 on ClinicalTrials.gov